Cellectar Cuts Q2 Losses and Expenses
Cellectar Biosciences (NASDAQ:CLRB), a biotechnology company specializing in targeted cancer therapies, delivered its latest earnings results for the second quarter of fiscal 2025 on August 14, 2025. The most significant takeaway was a substantial reduction in operating expenses, particularly in research and development, as the company prepared for its next regulatory milestones. Net loss per share (GAAP) was $(3.39), narrowing from analyst expectations of $(3.72) (GAAP) As anticipated for a pre-commercial biotech, Cellectar did not report any revenue. Overall, the company demonstrated notable cost controls but remains highly dependent on securing additional funding for its advancing clinical pipeline in the coming months.
Source: Analyst estimates for the quarter provided by FactSet.
Cellectar develops targeted radiopharmaceuticals for cancer therapy. Its key innovation is the phospholipid ether drug conjugate (PDC) platform, designed to selectively deliver radioactive and therapeutic payloads into cancer cells. This approach aims to improve treatment effectiveness while reducing harm to healthy cells.
Source Fool.com
